Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
Merck & Co Inc (NYSE:MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent pneumococcal conjugate vaccine.
默沙東公司（紐約證券交易所代碼：MRK）發佈了評估該公司在研的21價肺炎球菌偶聯疫苗V116的 STRIDE-3 3期試驗結果。
The trial evaluated the immunogenicity, tolerability, and safety of V116 compared to Pfizer Inc's (NYSE:PFE) Prevnar 20 (PCV20) in adults who had not previously received a pneumococcal vaccine.
該試驗評估了V116與輝瑞公司（紐約證券交易所代碼：PFE）Prevnar 20（PCV20）在以前未接種過肺炎球菌疫苗的成年人中的免疫原性、耐受性和安全性。
In adults 50 years of age and older (Cohort 1), V116 elicited non-inferior immune responses compared to PCV20 for all 10 serotypes common to both vaccines as measured by serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at Day 30.
在50歲及以上的成年人（隊列1）中，根據血清型特異性食管細胞活性 (OPA) 幾何平均滴度 (GMT) 在第30天測量，與兩種疫苗共有的全部10種血清型相比，V116引起的免疫反應並不遜色。PCV20
In adults 18 to 49 (Cohort 2), V116 elicited non-inferior immune responses (immunobridged) compared to adults 50 to 64, as assessed by serotype-specific OPA GMTs 30 days post-vaccination.
根據疫苗接種後30天血清型特異性OPA GMTs的評估，在18至49歲的成年人（隊列2）中，與50至64歲的成年人相比，V116引起的免疫反應不遜色（免疫橋接）。
Across both cohorts, V116 had a safety profile comparable to PCV20.
在這兩個隊列中，V116 的安全性與 PCV20 相當。
The V116 Phase 3 clinical development program comprises eight trials (n=8,830) investigating the safety, tolerability, and immunogenicity of V116 in various adult populations.
V116 3期臨床開發計劃包括八項試驗（n=8,830），調查V116在不同成年人群中的安全性、耐受性和免疫原性。
V116 utilizes the CRM197 vaccine carrier protein, produced using Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) patent-protected Pelican Expression Technology platform. If approved, Ligand is entitled to a royalty on worldwide net sales.
V116 採用 CRM197 疫苗載體蛋白，該蛋白使用受專利保護的 Ligand Pharmicals Incorporated Incorporated（納斯達克股票代碼：LGND）生產的。如果獲得批准，Ligand有權獲得全球淨銷售額的特許權使用費。
In July, Merck announced topline results from two Phase 3 trials evaluating V116 in vaccine-naïve and previously vaccinated individuals.
7月，默沙東公佈了兩項針對未接種疫苗和以前接種過疫苗的人群評估V116的三期試驗的總體結果。
Price Action: MRK shares are down 0.84% at $100.58 on the last check Tuesday.
價格走勢：週二MRK股價下跌0.84％，至100.58美元。
譯文內容由第三人軟體翻譯。